Are We Overtreating DCIS?

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Data from the phase 3 CheckMate-67T trial support the CHMP’s recommendation for approving subcutaneous nivolumab across various solid tumor indications.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Ariana Pelosci

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

An expert panel at ELCC 2025 reviews the MARIPOSA trial's implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Leticia Nogueira, PhD, MPH

Solnerstotug Shows Promising Preliminary Data in PD-L1 Resistant Tumors

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

No dose-limiting toxicities were seen with solnerstotug in patients with PD-L1–resistant tumors, and most adverse effects were grades 1/2 in severity.

Roman Fabbricatore

HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

No dose-limiting toxicities were seen with solnerstotug in patients with PD-L1–resistant tumors, and most adverse effects were grades 1/2 in severity.

Tim Cortese

EU’s CHMP Has Positive Opinion for Subcutaneous Nivolumab in Solid Tumors

Muhammed Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.

Related Content

Russ Conroy

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Data from the phase 3 CheckMate-67T trial support the CHMP’s recommendation for approving subcutaneous nivolumab across various solid tumor indications.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Ariana Pelosci

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

An expert panel at ELCC 2025 reviews the MARIPOSA trial's implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.

Leticia Nogueira, PhD, MPH

Solnerstotug Shows Promising Preliminary Data in PD-L1 Resistant Tumors

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Roman Fabbricatore

HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

No dose-limiting toxicities were seen with solnerstotug in patients with PD-L1–resistant tumors, and most adverse effects were grades 1/2 in severity.

Tim Cortese